WO2005067970A1 - 鉄補給剤及びその利用 - Google Patents
鉄補給剤及びその利用 Download PDFInfo
- Publication number
- WO2005067970A1 WO2005067970A1 PCT/JP2005/000313 JP2005000313W WO2005067970A1 WO 2005067970 A1 WO2005067970 A1 WO 2005067970A1 JP 2005000313 W JP2005000313 W JP 2005000313W WO 2005067970 A1 WO2005067970 A1 WO 2005067970A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- iron
- siderophore
- food
- ferric ion
- food composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Definitions
- the present invention relates to an iron supplement using a siderophore, an agent for preventing or treating iron deficiency anemia, a food additive, and a food composition.
- iron deficiency anemia causes various adverse effects on the human body, such as reduced exercise and learning abilities, and reduced immunity.
- it is generally considered effective to ingest meat or fish containing a large amount of heme iron which is easily absorbed by humans.
- ingesting large amounts of meat or fish requires drastic changes in dietary habits, and excessive intake of these will result in poor nutritional balance.
- iron contained in plants such as vegetables is non-heme iron, and the absorption rate of non-heme iron is about 1Z2 to 1Z5, which is the absorption rate of heme iron.
- absorption of non-heme iron is easily inhibited by dietary fiber and catechins contained in green tea. Therefore, it is not realistic to get enough iron from plants.
- iron preparations such as iron pyrophosphate, iron citrate, and iron sulfate have been used to prevent or treat anemia by supplementing iron.
- the iron contained in these iron preparations generally has a low utilization rate in vivo, so that it is necessary to take large amounts in order to obtain the effect of preventing or treating anemia.
- it is difficult to ingest a large amount of these iron salts in a short period of time because a large amount of these iron salts may cause gastrointestinal mucosal damage or vomiting. Therefore, in order to obtain the effect of preventing or treating anemia, it is necessary to take these iron salts for a long period of time. It is necessary.
- Ratatoferrin is known to be a glycoprotein having iron binding ability.
- Patent Literature 1 discloses a blood increasing effect of an iron ratatoferin complex and a method for producing the same.
- the iron ratatoferin complex is poorly soluble and requires the consumption of a large amount of lactoferrin for the required amount of iron, there are still many issues to be solved before it can be used as an iron preparation. I have.
- Non-Patent Document 1 discloses the results of an investigation on the absorption of an iron fortifier containing EDTA-FeNa as an active ingredient.
- EDTA has a strong chelating effect on many trace metals in the living body, it may inactivate the necessary metals in the living body by chelation. Long-term intake of iron fortifiers is a health concern.
- Non-patent Document 1 "Micronutrient Research", Vol. 18, pp. 25-28 (2001)
- Anemia due to iron deficiency is the first stage of liver iron deficiency, serum iron deficiency It progresses through the second stage, and the third stage in which hemoglobin synthesis ability decreases and anemia appears. Iron deficiency anemia recovers through the reverse phase.
- the siderophore trivalent iron chelate complex when ingested by iron-deficient anemic rats, is efficiently absorbed into the living body to increase the serum iron concentration and blood hemoglobin concentration, and further increases the liver concentration.
- the stored iron also increases the calories. Therefore, the siderophore trivalent iron chelate complex is useful as an agent for preventing, ameliorating or treating various symptoms caused by iron deficiency, particularly iron deficiency anemia.
- Liquid food compositions containing 0.05-lOmgZml of siderophore trivalent iron chelate complex are impossible! It is possible to effectively prevent or ameliorate iron deficiency anemia by taking an intake schedule and cause side effects. Absent.
- the solid food composition containing 0.1-5 mg / g of a siderophore trivalent iron chelate complex can effectively prevent or ameliorate iron deficiency anemia on an inexpensive schedule. No side effects occur.
- the present invention has been completed based on the above findings, and provides the following iron supplements and the like.
- Item 1 An iron supplement containing a siderophore and ferric ion.
- Item 2 The iron supplement according to item 1, wherein the siderophore and the ferric ion are contained in the form of a chelate complex.
- Item 3 The iron supplement according to Item 1 or 2, wherein the siderophore contains hydroxamic acid.
- Item 4 The iron supplement according to Item 3, which is the chelate complex ferrichrome.
- Item 5. The iron supplement according to item 4, wherein the ferrichromes are huerychrysin.
- Item 6 An agent for preventing or treating iron deficiency anemia, comprising a siderophore and ferric ion.
- Item 7 The preventive or therapeutic agent for iron deficiency anemia according to Item 6, wherein the siderophore and the iron (III) ion are contained in the form of a chelate complex.
- Item 8 The preventive or therapeutic agent for iron deficiency anemia according to Item 6 or 7, wherein the siderophore contains hydroxamic acid.
- Item 9 The agent for preventing or treating iron deficiency anemia according to Item 8, wherein the chelate complex is a ferrichrome.
- Item 10 The preventive or therapeutic agent for iron deficiency anemia according to Item 9, wherein the ferrichrome is phulicrisin.
- Item 11 A food additive for supplementing iron, comprising a siderophore and ferric ion.
- a food additive for preventing or ameliorating iron deficiency anemia comprising a siderophore and ferric ion.
- Item 13 A food composition comprising a siderophore and ferric ion.
- Item 14 The food composition according to item 13, wherein the siderophore and the iron (III) ion are contained in the form of a chelate complex.
- Item 15 The food composition according to item 13 or 14, wherein the solid food composition contains 0.1 to 5 mg / g of siderophore and ferric ion in terms of a chelate complex. .
- Item 16 The food composition according to item 13 or 14, wherein the liquid food composition contains 0.05-lOmgZml of a siderophore and ferric ion in terms of a chelate complex.
- Item 17 The food composition according to item 16, wherein the food is a beverage selected from the group consisting of liquors, teas, coffees, sports drinks, soft drinks, dairy drinks, and soup powers.
- Item 18 The food composition according to any one of Items 13 to 17 for iron supplementation.
- Item 19 The food composition according to any one of Items 13 to 17 for preventing or improving iron deficiency anemia.
- Item 20 A food composition according to any one of the following (0— (vi)), which comprises a siderophore and a ferric ion.
- a food composition characterized by having an effect of adding iron and having a label indicating that it is used for adding iron.
- a food composition characterized by having an action to maintain the iron content in the body to a normal level, and labeled to be used to maintain the iron content in the body to a normal level.
- a food composition characterized by having an action of eliminating or reducing iron deficiency in the body and indicating that it is used to eliminate or reduce iron deficiency in the body.
- Item 21 A method for iron supplementation comprising administering a composition comprising a siderophore and ferric ion to a human.
- Item 22 Converting the siderophore and the iron (III) ion into a chelate complex at a rate of 20—1 per day
- Item 24 The iron supplementation method according to Item 21 in which 70 mg is administered.
- Item 23 A method for preventing or treating iron deficiency anemia, comprising administering a composition comprising a siderophore and ferric ion to a human.
- Item 24 Converting the siderophore and the iron (III) ion into a chelate complex at a rate of 20—1 per day
- Item 24 The method for preventing or treating iron deficiency anemia according to Item 23, wherein 70 mg is administered.
- Item 25 A method of adding a composition containing a siderophore and a ferric ion to a food.
- Item 26 Use of a composition containing a siderophore and ferric ion as an iron supplement.
- Item 27 Use of a composition containing a siderophore and ferric ion as an agent for preventing or treating iron deficiency anemia.
- Item 28 Use of a composition containing a siderophore and ferric ion as a food additive for iron supplementation.
- Item 29 Use of a composition containing a siderophore and ferric ion as a food additive for preventing or ameliorating iron deficiency anemia.
- Item 30 Use of a composition containing a siderophore, ferric ion and food as a food composition for iron supplementation.
- Item 31 Use of a composition containing a siderophore, ferric ion and food as a food composition for preventing or ameliorating iron deficiency anemia.
- iron (II) ions have a higher absorption rate in the living body, but the present inventor has found that the trivalent iron chelate complex of the siderophore is efficiently absorbed in the living body. It was first found to increase serum iron levels, blood hemoglobin levels, and stored iron levels in the liver.
- a composition containing a siderophore and ferric ion can be suitably used as a pharmaceutical preparation such as an iron supplement or an agent for preventing or treating iron deficiency anemia.
- a food composition containing a siderophore and ferric ion can supplement iron and prevent or improve iron deficiency anemia.
- the food can be provided with an iron supplementing effect and an effect of preventing or ameliorating iron deficiency anemia.
- the iron chelate complex Since the iron chelate complex is originally contained in food using koji such as sake or sake lees, its safety has been proven historically. In addition, as described later, it was found that the liver function, the renal function, the amount of weight gain, the amount of food consumed, and the like were not reduced, and the living body was not adversely affected. Therefore, it is suitable for continuous use not only for improvement or treatment of various symptoms due to iron deficiency, but also for prevention. Similarly, it is also suitable as a functional food or a special health food to be taken by healthy people.
- forming a complex is in a lower energy state, that is, a chemically stable state, than when a ligand and a metal ion are present separately.
- the siderophore does not show the effect of promoting the peroxide formation reaction exhibited by iron ions. (Metal. Lons Biol. Syst., Vol. 35, p37)
- siderophores are highly useful as foods and pharmaceuticals in that they do not promote the production of peroxidized harmful substances.
- the chelate complex of a siderophore and a ferric iron ion is hard to be insoluble even in the presence of a substance such as phytic acid or tannic acid, which is generally known as a food ingredient that makes iron insoluble. Therefore, regardless of the food, the siderophore and the iron (III) ion can efficiently obtain the effect of supplementing iron and the effect of preventing or treating iron deficiency anemia.
- the iron supplement and the preventive or therapeutic agent for iron deficiency anemia of the present invention contain a siderophore and ferric ion, and particularly contain this as an active ingredient.
- the siderophore and the ferric iron ion may be contained separately, or may be contained as a chelate complex.
- Standard mouth fore includes compounds that can chelate ferric iron ions.
- the origin of the siderophore is not particularly limited, and may be derived from any organism. Many microorganisms produce siderophores to efficiently take in iron, an essential component, when the external iron concentration is low. Since microorganisms can be easily propagated, siderophores can be easily mass-produced by using microorganisms. In this regard, siderophores derived from microorganisms are preferred. Furthermore, a host that produces a large amount of siderophore can be easily prepared by recombination of the gene encoding the siderophore synthase group. Also in terms of hornbeam fores derived from microorganisms are preferred.
- the type of siderophore derived from a microorganism is not particularly limited.
- catechols such as enterobactin, vibriobactin, aglobatatin, and anguibatatin
- Hydroxamates such as fuzarinin C
- polycarboxylates such as lysoferrin.
- hydroxamates siderophores containing hydroxamic acid
- cyclic ferrichromes are more preferable in terms of stability.
- Ferrichromes are a general term for cyclic peptide compounds containing three hydroxamic acids, and include compounds represented by the following general formula (1).
- R 1 represents a hydrogen atom or a hydroxymethyl group
- R 2 represents a hydrogen atom, a methyl group or a hydroxymethyl group
- R 3 , R 4 , R 5 are the same or different, methyl, N 5 - (trans-5-hydroxy-3-methylpent - 2 Enoiru) group, N 5 - (cis - 5-hydroxy-3-methylcarbamoyl Rupento - 2 Enoiru) group, or N 5 (trans 4 Karubokishi 3- Represents a methylpent-2-enyl) group.
- ferrichrome is preferred because its safety has been historically confirmed.
- huelicrisin is preferable in terms of good productivity since Aspergillus oryzae is produced in a relatively large amount.
- a natural siderophore derivative having a chelating effect of ferric iron can be used in addition to a natural siderophore.
- derivatives of natural siderophores include those that are acetylated and nitrated, those that are partially substituted with amino acids, and the like.
- Siderophores can be produced by recovery from living organisms. When organisms are grown under iron limitation, iron-free dehueoli bodies are produced. By adding iron to this dephenyl body, usually, a complex obtained by chelating a ferric ion is obtained.
- the siderophore recovered from the organism may be a crude preparation or purified.
- the siderophore may be purified by a known purification method, for example, various types of chromatography such as ion exchange, hydrophobicity, gel filtration, and affinity.
- chromatography such as ion exchange, hydrophobicity, gel filtration, and affinity.
- the product produced in the supernatant may be recovered by liquid culture, or the solid culture may be extracted using water or a buffer. It may be recovered from the liquid!
- the iron supplement and the preventive or therapeutic agent for iron deficiency anemia of the present invention may contain, for example, biologically-derived contaminants even if the difference is V ⁇ .
- Siderophores can also be purchased commercially. Also, a mixture of these siderophores may be used.
- Defelihuelicrisin a ligand constituting fuericrisin
- a ligand constituting fuericrisin is one of ferrichromes known to produce large amounts of Aspergillus oryzae in koji making (solid culture).
- Most of the ferrichromes produced by Aspergillus oryzae are deferrihuelicrisins.
- Deferiphelicrisin chelate ferric ions into ferricrissin.
- Defferihuelicrisin is recovered from Aspergillus oryzae by the following method. be able to.
- a medium for culturing Aspergillus oryzae for example, a potato dextrose medium (Nissi) or a minimal medium (2% glucose (or starch), 0.3% NaNO, 0.2% KC1, 0.1% KHPO) , 0.05% MgSO, pH 6.0)
- the medium may be a solid medium or a liquid medium, but it is preferable to use a liquid medium from the viewpoint of easy recovery of defferic erychrysin. Further, a solid medium such as rice koji is also preferable in that it can be used as it is in a food product without recovering and refining deferriferichrysin therefrom.
- the culture temperature may be any temperature within a temperature range in which Aspergillus * oryzae can grow, for example, about 25 to 42 ° C.
- the cultivation time may vary depending on other conditions.
- the cultivation time may be about 2 to 7 days.
- the cells are filtered, and then the fermentin is recovered from the culture solution. Furthermore, the culture supernatant is subjected to various protein purification methods known in the art, for example, various types of chromatography such as ion exchange, hydrophobicity, gel filtration, and affinity, to obtain purified defferihuelicrisin.
- various protein purification methods known in the art, for example, various types of chromatography such as ion exchange, hydrophobicity, gel filtration, and affinity, to obtain purified defferihuelicrisin.
- the mixing of the siderophore (dephenyle form) with the ferric ion usually produces a chelate complex quickly.
- trivalent iron ions are in the form of a chelate complex with siderophore and are present in the blood hemoglobin concentration, serum iron concentration, and liver. Improve iron concentration effectively.
- the ratio between the siderophore and the iron (III) ion contained in the iron supplement and the preventive or therapeutic agent for iron deficiency anemia is usually preferably about 5: 1 to 1: 1 in terms of molar ratio. About 1 is more preferable. It is usually most preferable that the siderophore and the ferric iron ion be contained in the same molar amount.
- the iron supplement and the preventive or therapeutic agent for iron deficiency anemia of the present invention can be produced by mixing or combining siderophore and ferric ion.
- the siderophore and the ferric ion preferably a chelate complex thereof, contain various pharmaceutically acceptable carriers. (Including excipients, binders, disintegrants, lubricants, humectants, etc.) to give appropriate formulations.
- the formulation may also contain conventional additives.
- the formulation is not particularly limited, and is, for example, an oral administration preparation such as a tablet, a pill, a capsule, a powder, a granule, a capsule, an injection, a drip, an external preparation, a suppository, and the like.
- an oral administration preparation such as a tablet, a pill, a capsule, a powder, a granule, a capsule, an injection, a drip, an external preparation, a suppository, and the like.
- Various preparation forms such as parenteral administration preparations can be mentioned.
- Orally administered drugs are easier to use because they place less burden on patients than parenterally administered drugs.
- siderophore and ferric ion can effectively increase serum iron concentration, blood iron concentration, and hepatic iron concentration when administered orally in combination, It can be suitably used in the form of an oral administration preparation.
- excipient a wide variety of known excipients can be used, for example, various sugars such as lactose, sucrose, glucose, etc., various starches such as potato starch, wheat starch, corn starch, crystalline cellulose and the like. Examples include various celluloses, various inorganic salts such as anhydrous calcium hydrogen phosphate and calcium carbonate.
- binder known binders can be widely used, and examples thereof include crystalline cellulose, pullulan, acacia, sodium alginate, polybutylpyrrolidone, macrogol and the like.
- disintegrant known ones can be widely used, and examples thereof include carboxymethylcellulose, carboxymethylcellulose calcium, hydroxypropylcellulose, hydroxypropylstarch, starch, and sodium alginate.
- Lubricants include magnesium stearate, talc, hardened oil and the like.
- humectant known humectants can be widely used, and examples thereof include coconut oil, olive oil, sesame oil, peanut oil, soybean phospholipid, glycerin, and sorbitol.
- the content of siderophore and ferric ion in the preparation varies depending on the type of siderophore, administration route, age, weight, symptoms, etc. of the administration subject or patient, and cannot be specified unconditionally.
- the daily dose in the form may be usually about 20-170 mg, more preferably about 40-80 mg. In the case of once-daily administration, it is sufficient that this amount is contained in one product. In the case of three-times-daily administration, one-third of this amount should be contained in one product.
- the preparation contains about 5 to 30% by weight of siderophore and trivalent iron in terms of a chelate complex.
- the siderophore and ferric iron are contained in an amount of about 0.2 to 1% by weight in terms of a chelate complex.
- the siderophore and trivalent iron are contained in an amount of about 0.4 to 2% by weight in terms of a chelate complex.
- the siderophore and trivalent iron are contained in an amount of about 110% by weight in terms of a chelate complex.
- siderophores and trivalent iron and may be contained 2-20 wt 0/0 degree in terms of chelating complexes. When the content is within the above range, the iron supplementing effect or the effect of preventing or treating iron deficiency anemia is sufficiently obtained, and no side effect appears.
- the food additive of the present invention is an additive containing a siderophore and ferric ion. These may be included in the form of a chelate complex. This additive can be suitably used as an additive for imparting an iron supplementing action to a food or a preventive or ameliorating action for iron deficiency anemia.
- the food additive may contain carriers such as sugars, starches, cellulose, magnesium stearate, and vegetable oil, and additives, in addition to the siderophore and ferric ion.
- carriers and additives are included in food additives, the content of siderophore and ferric ion can be approximately 0.4 to 4% by weight for solid preparations in terms of chelate complex. In the case of liquid preparations, it can be about 0.04 to 0.4% by weight.
- the preferred ratio of siderophore to ferric ion is as described for the pharmaceutical formulation.
- the dosage form of the food additive is not particularly limited, but may be, for example, a dosage form such as powder, granule, and liquid. n) Ito
- the food composition of the present invention is a composition containing a siderophore and a ferric ion, preferably as a chelate complex.
- the food composition has an iron supplementation (in other words, iron supplementation, iron fortification, iron addition, maintaining a normal iron content in the body, eliminating or reducing iron deficiency in the body), an iron deficiency, and the like. Since it has a preventive or ameliorating effect on ischemic anemia, it can be a food composition with a label indicating that it is used for these purposes. This food composition can be suitably used as a functional food or a food for specified health use. In this case, the complex is contained as an active ingredient.
- Siderophore trivalent iron complex is a component conventionally contained in sake, and does not have a taste or smell that would impair the flavor of food. Therefore, the type of food is not particularly limited.
- the type of food is not particularly limited.
- alcoholic beverages that are preferred for liquid foods such as beverages and liquid seasonings such as sauces, dressings, soy sauces, vinegars and flavors; Beverages such as teas, coffees, sports drinks, soft drinks, milk drinks, and soups are more preferred. Most preferred are liquors, teas, coffees, sports drinks, and soft drinks.
- the compound since the compound exhibits high water solubility even under low ⁇ conditions where the water solubility of the iron compound may decrease, there is an advantage that it can be suitably used as an additive for liquid acidic foods such as mayonnaise and dressings.
- foods to which the iron supplement of the present invention is added can be sterilized by heat and pressure, and can also undergo a special manufacturing process such as retort treatment. Furthermore, since siderophore is conventionally contained in foods using koji, its safety has been historically confirmed. It is suitable.
- the content of the siderophore and ferric ion in the food composition varies depending on the type of the siderophore, the age, weight, symptoms, etc. of the administration subject or the patient, and cannot be unconditionally specified.
- the daily intake capacity should be about 20-170 mg, especially about 40-80 mg.
- the concentration of siderophore and iron (III) ions in foods varies depending on the type of foods and the like.
- the concentration is preferably about 0.1 to 5 mgZg in terms of chelate complex. 0.2-3mgZg is more preferred 0.25-1.5mgZg is even more preferred
- a liquid food it is preferably about 0.05 to 10 mg / ml in terms of a chelate complex, more preferably about 0.1 to 5 mgZml, and still more preferably about 0.2 to 1 mgZml.
- Forces that vary depending on the form of food The usual intake of a solid food is about 10-50 g, and the intake of a liquid food is about 50-500 ml. Can supply the necessary iron ions a day. Within the above range, a sufficient iron supplementing effect or an effect of preventing or ameliorating iron deficiency anemia can be obtained, and there is no possibility of iron overload.
- alcoholic beverages, especially sake, containing siderophore and ferric ion in the above-mentioned ratios are effective for iron deficiency anemia, do not cause side effects, and are more effective for drinking. No discomfort.
- the food composition of the present invention can be added and blended with various additive carohydrates commonly used in the preparation of food compositions.
- additives include stabilizers, pH adjusters, sugars, sweeteners, flavors, various vitamins, minerals, antioxidants, excipients, solubilizers, binders, lubricants, and lubricants.
- Columns f, turbidity, wetting agents, film-forming substances, flavoring agents, flavoring agents, coloring agents, preservatives, etc. can be shown.
- the food composition of the present invention can also be suitably used as a dietary supplement for supplementing iron or preventing or ameliorating iron deficiency anemia, ie, a supplement.
- the food composition may contain a component known as a carrier of the supplement, in addition to the siderophore and ferric ion.
- Such carriers include, for example, sugars, starches, cellulose, magnesium stearate, and vegetable oils.
- the content of the siderophore and the iron (III) ion in the supplement is preferably from about 30 mg to 300 mg, more preferably from about 60 mg to 200 mg, in terms of a chelate complex. Within the above range, sufficient effects of iron supplementation and prevention or amelioration of iron deficiency anemia can be obtained, and side effects do not appear due to excessive amounts.
- the shape of the supplement is not particularly limited, and examples thereof include a tablet, a powder, and a granule.
- the siderophore trivalent iron chelate complex has a high absorption rate of iron into the body, so administration of the siderophore and trivalent iron ions to humans replenishes iron and causes anemia due to iron deficiency.
- iron deficiency anemia can be effectively prevented, ameliorated or treated.
- the subject to which the iron supplement and the composition for iron supplement are administered may be any of humans or healthy persons exhibiting symptoms due to iron deficiency. In addition, growing children and adult women who are susceptible to iron deficiency are also suitable administration targets.
- the dose varies depending on the type of siderophore, the symptom, age, body weight, etc. of the siderophore.
- the daily dose in the form of a power chelate complex is about 20 to 170 mg, especially about 40 to 80 mg per day. It may be administered once or in several divided doses.
- the route of administration may be oral or parenteral! /, But even in the case of oral administration, it is possible to effectively increase serum iron concentration. I like it.
- Salt Mixture 1 and Salt Mixture 2 in Table 2 above were prepared according to Harper Mineral Mixture, and are mixtures having compositions shown in Table 3 below.
- the vitamin mixture in Table 2 was prepared according to AIN-76 vitamin (added with choline), and was a mixture having the composition shown in Table 4 below.
- Vitamin D 3 10,000 IU
- iron-containing feed 1 contains ferric citrate as an iron source
- iron-containing feed 2 contains water-soluble heme iron as an iron source
- iron-containing feed 3 contains ferriclysin as an iron source.
- the composition of iron-containing feeds 12 and 3 is shown in Table 5 below.
- the iron-containing feed 1 is the same as that shown in Table 2.
- Salt mixtures 23 and 4 in Table 5 are mixtures whose compositions are shown in Table 6 below.
- the vitamin mixture in 5 is a mixture whose composition is shown in Table 4 above.
- Fe-citrate (Fe 173 ⁇ 4) 0.45 0 0
- the rats in each group to which the iron-containing diet 1 (ferric taenoate), the iron-containing diet 2 (heme iron) and the iron-containing diet 3 (felikrysin) were administered, respectively, were fed.
- the control rats to which the iron-containing feed 1 (ferric citrate) was administered from the beginning received the iron-containing feed 1.
- the results are shown in Table 7 below.
- the values in Table 7 are The mean value of the hemoglobin concentration of 5 animals in each group is shown.
- Control group 106.2 ⁇ 4.7 serum iron levels increased to the same level as those in the control group in the group that received the diet containing ferric citrate or pherychrysin as the iron source. On the other hand, serum iron was significantly reduced in the group that took water-soluble heme iron, and a significant difference was observed at the level of 1% risk compared to the control group. Thus, the second step in iron deficiency anemia In the group that took huelicrisin, the same improvement effect as that of ferric citrate was observed, and a significantly superior improvement effect was observed as compared with iron heme.
- iron-containing diet 1 iron-containing diet 1
- iron-containing diet 2 iron-containing diet 2
- iron-containing diet 3 iron-containing diet 3
- ALT alanine aminotransferase
- AST aspa Laginate aminotransferase
- iron-containing diet 1 iron-containing diet 1
- iron-containing diet 2 heme iron
- iron-containing diet 3 iron-containing diet 3
- the solubility of huelicrisin was compared with other iron compounds.
- the concentration of the buffer in each buffer was 0.1 mol ZL. After keeping each buffer solution warm, it was centrifuged, and the presence or absence of a precipitate was visually confirmed. Also, the iron concentration in the supernatant
- huelicrisin was extremely water-soluble and highly potent. It is known that some iron compounds precipitate under acidic conditions. As is clear from the above results, ferric chloride and ferric iron also precipitate under acidic conditions. In contrast, huelicrisin showed high water solubility even under acidic conditions. It is considered that iron of pherychrysin acquired high water solubility by becoming a trivalent force complex. This has made it easy to use in vivo.
- Phericrisin which was also prepared as described above, was also dissolved in ultrapure water to a concentration of 2.5 mgZml. Further, dilution was performed using the following buffers so that the concentration of pherychrysin was 0.25 mg / ml.
- An acid buffer was used
- the concentration of the buffer in each buffer was 0.1 mol ZL.
- ferriculisin, ferric citrate, and sodium ferrous citrate prepared by the above-described method were each dissolved in ultrapure water so as to be lOmgZml as iron.
- 0.6% aqueous solutions of tannic acid and phytic acid were prepared.
- the pH of this aqueous solution was adjusted to 2.0, 4.0, 6.0, and 8.0 with hydrochloric acid or sodium hydroxide, respectively, to prepare them.
- the iron compound solution and the tannic acid aqueous solution are mixed with a phytic acid aqueous solution at a volume ratio of 1: 9, and the mixture is incubated at 37 ° C for 3 hours to convert the iron compound and these iron absorption inhibiting components. Reacted.
- This solution was centrifuged at 15000 rpm for 5 minutes, and the supernatant was subjected to ultrafiltration using a membrane having a molecular weight cut off of 10,000.
- the iron concentration of the filtrate was measured by the atomic absorption method. Table 14 below shows the ratio of the iron concentration after the reaction to the initial iron concentration (lmgZml) in the reaction solution, expressed as a percentage.
- Pherychrysin 80.5 71.8 76.1 81.9 As shown in Table 14, it is related to the insolubility of iron. The reactivity between the two components and huelicrissin was low, and the high solubility of iron was maintained. This phenomenon was almost constant from pH 2.0 to 8.0, and was significantly higher than other iron compounds. It has a very high chemical stability because pherychrysin is a complex containing iron, and it is difficult to react with other food ingredients. This seems to have contributed. This result suggests that iron is efficiently absorbed even when huerychrysin is ingested with a food having an iron-insoluble dandruff action.
- the concentration of huelicrisin in the obtained iron-enriched cookies was 0.05 mgZg, 0.1 mg / g, 0.2 mgZg, 0.5 mgZg, 1.5 mgZg, 3.OmgZg, 5.OmgZg, 10 mg / g, 20mg / g is there.
- the cookie is not more than 3 mg / g (0.3% by weight), particularly not more than 1.5 mg / g (0.15% by weight), more particularly 0.5 mgZg (0.05% by weight). %) When added in the following range, the sensory evaluation was good.
- 1200 g of milk, 310 g of fresh cream, 300 g of white sucrose, 60 g of skim milk powder, lg of defatted egg yolk protein decomposed product, 6 g of thickening stabilizer, 800 mg of huelicrisin, and water were added to make a total volume of 2000 ml and dissolved. After heating this to 80 ° C, it was pre-emulsified with a homomixer and subsequently homogenized. After cooling and aging, 2 g of vanilla essence was added to perform freezing. Thereafter, the mixture was rapidly cooled to ⁇ 40 ° C. to obtain an iron-enriched ice cream. The resulting ice cream contained 0.4 mg / g of huelicrisine.
- the inoculum of Streptococcus thermophilus and Lactobacillus casei was cultured to obtain 400 g of yogurt base.
- Sarako, sugar 70 g, pectin 3 g, and huerychrysin 800 mg were dissolved in water, and water was added to make the total amount 600 g.
- This solution was sterilized at 120 ° C. for 3 seconds to obtain a syrup.
- the above-mentioned yogurt base and syrup were mixed, fragrance was added by lg, and the mixture was homogenized to obtain iron-reinforced yogurt.
- the obtained yogurt contained 0.8 mg / g of huerychrysin.
- huelicrisin 40 mg was added to 100 ml of milk and mixed well to obtain iron-enriched milk.
- the resulting milk contained 0.4 mg / ml of huelicrisin.
- ⁇ Prescription example 9 mayonnaise> To 20 g of yolk, add 2.5 g of salt, 1.5 g of sucrose, 1.5 g of mustard, 0.1 g of pepper, 5 g of lemon juice, 3.2 g of ferricrisin, add 10 g of vinegar and 160 g of salad oil, and mix well. As a result, iron-fortified mayonnaise was obtained. The resulting mayonnaise contained 16 mg Zg of huerychrysin.
- a small amount of water was added to 125 g of flour (light flour), 100 g of butter, 20 g of curry powder, and 1.Og of huerychrysin, and the mixture was solidified to obtain iron-enriched Carrele II.
- the obtained Carrera II contained ferricillin power mg / g.
- ⁇ Prescription example 15 150 g of white rice, 220 g of water and 160 mg of huelicrisin were mixed and cooked in a rice cooker to obtain iron-enriched cooked rice. The resulting cooked rice contained 0.5 mg / g of huelicrisin.
- huelicrisin 40 mg was added to 100 ml of shochu and stirred well to obtain an iron-enriched shochu.
- the obtained shochu contained 0.4 mg Zml of huerychrysin.
- huelicrisin 20 mg was added to 100 ml of wine and stirred well to obtain an iron-fortified wine.
- the resulting wine contained huelicrisin at 0.2 mg / ml.
- huerychrysin 12 mg was added to 100 ml of beer and stirred to obtain an iron-enriched beer.
- the resulting beer contained 0.12 mg Zml of huelicrisin.
- huelicrisin 400 mg was added to 100 ml of mirin and stirred well to obtain iron-fortified mirin.
- the resulting mirin contained 4 mg Zml of huelicrisin.
- huelicrisin 40 mg was added to 100 ml of tea and stirred well to obtain an iron-fortified tea.
- the resulting tea contained 0.4 mg / ml of huelicrisin.
- Phericlicin 40 mg was added to 100 ml of coffee and stirred well to obtain iron-fortified coffee.
- the resulting coffee contained 0.4 mg / ml of huerychrysin.
- Phagelicin 40mg was added to 100ml potage soup and stirred well to obtain iron-enriched soup.
- the resulting soup contained 0.4 mg / ml of huelicrisin.
- the iron supplement of the present invention can prevent and improve symptoms caused by iron deficiency including iron deficiency anemia. Alternatively, it can be suitably used for treatment. Further, the food additive of the present invention can be suitably used as a functional food for supplementing iron, or for preventing or improving iron deficiency anemia, or as an additive to a food for specified health use.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/585,879 US20080113899A1 (en) | 2004-01-14 | 2005-01-13 | Iron Supplement and Utilization of the Same |
EP05703552A EP1704871A4 (en) | 2004-01-14 | 2005-01-13 | IRON COMPLEMENT AND USE |
CA002552889A CA2552889A1 (en) | 2004-01-14 | 2005-01-13 | Iron supplement and utilization of the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-007278 | 2004-01-14 | ||
JP2004007278 | 2004-01-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005067970A1 true WO2005067970A1 (ja) | 2005-07-28 |
Family
ID=34792177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/000313 WO2005067970A1 (ja) | 2004-01-14 | 2005-01-13 | 鉄補給剤及びその利用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20080113899A1 (ja) |
EP (1) | EP1704871A4 (ja) |
CA (1) | CA2552889A1 (ja) |
WO (1) | WO2005067970A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008020260A2 (en) * | 2006-08-16 | 2008-02-21 | R-Ko-N Kft. | Use of siderophores in prevention of vascular diseases, production of siderophores and qualifying siderophore containing meat-products |
WO2020031141A1 (en) * | 2018-08-10 | 2020-02-13 | Cura Global Health (Bvi) Limited | Method for treating iron deficiency |
JP2021530515A (ja) * | 2018-07-19 | 2021-11-11 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | 鉄欠乏症および関連する貧血を治療するためのエンテロバクチンの新規使用のための方法、システムおよび組成物 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090110640A1 (en) * | 2006-03-29 | 2009-04-30 | Oskar Axelsson | Contrast agents for magnetic resonance imaging and spectroscopy consisting of a cyclic oligoamid core of 3 to 4 identicial monomer units with 3 to 4 paramagnetic chelate side chains |
CN109223724A (zh) | 2009-07-21 | 2019-01-18 | 凯克斯生物制药公司 | 柠檬酸铁剂型 |
UA113419C2 (xx) * | 2011-12-14 | 2017-01-25 | Емульгований харчовий продукт із вмістом молочного білка | |
AU2014206815A1 (en) * | 2013-01-18 | 2015-07-23 | Nestec S.A. | Food composition comprising desferrichrysin |
KR20170123664A (ko) * | 2015-03-04 | 2017-11-08 | 케릭스 바이오파마슈티컬스 인코포레이티드 | 철-결핍성 빈혈의 치료에서 구연산철의 용도 |
MY193585A (en) * | 2016-12-15 | 2022-10-19 | Nestle Sa | Composition in powder form comprising iron-milk protein complexes and probiotic bacteria |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8410290D0 (en) * | 1984-04-19 | 1984-05-31 | Callingham B A | Pharmaceutical compositions |
US4767611A (en) * | 1984-07-03 | 1988-08-30 | Gordon Robert T | Method for affecting intracellular and extracellular electric and magnetic dipoles |
US5021567A (en) * | 1987-09-24 | 1991-06-04 | Abbott Laboratories | 8-hydroxyquinoline chelating agents |
JP3167402B2 (ja) * | 1992-02-25 | 2001-05-21 | 仙味エキス株式会社 | 鉄吸収促進組成物 |
JP2884045B2 (ja) * | 1994-03-18 | 1999-04-19 | 雪印乳業株式会社 | 鉄−ラクトフェリン複合体及びその製造法 |
US5665392A (en) * | 1995-07-11 | 1997-09-09 | Council Of Scientific And Industrial Research | Formulation for treating thalassemia and a process for preparing the same |
-
2005
- 2005-01-13 EP EP05703552A patent/EP1704871A4/en not_active Withdrawn
- 2005-01-13 WO PCT/JP2005/000313 patent/WO2005067970A1/ja active Application Filing
- 2005-01-13 CA CA002552889A patent/CA2552889A1/en not_active Abandoned
- 2005-01-13 US US10/585,879 patent/US20080113899A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008020260A2 (en) * | 2006-08-16 | 2008-02-21 | R-Ko-N Kft. | Use of siderophores in prevention of vascular diseases, production of siderophores and qualifying siderophore containing meat-products |
WO2008020260A3 (en) * | 2006-08-16 | 2008-10-02 | R Ko N Kft | Use of siderophores in prevention of vascular diseases, production of siderophores and qualifying siderophore containing meat-products |
JP2021530515A (ja) * | 2018-07-19 | 2021-11-11 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | 鉄欠乏症および関連する貧血を治療するためのエンテロバクチンの新規使用のための方法、システムおよび組成物 |
WO2020031141A1 (en) * | 2018-08-10 | 2020-02-13 | Cura Global Health (Bvi) Limited | Method for treating iron deficiency |
Also Published As
Publication number | Publication date |
---|---|
EP1704871A4 (en) | 2008-08-06 |
EP1704871A1 (en) | 2006-09-27 |
CA2552889A1 (en) | 2005-07-28 |
US20080113899A1 (en) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4931352B2 (ja) | 鉄補給剤及びその利用 | |
WO2005067970A1 (ja) | 鉄補給剤及びその利用 | |
WO2007040244A1 (ja) | 疲労自覚症状改善用組成物 | |
JP5128828B2 (ja) | 抗炎症剤及び抗酸化剤 | |
KR101243537B1 (ko) | 액체 조미료 | |
JP2002065212A (ja) | 筋強化用食品組成物及び筋強化剤 | |
JP2014237715A (ja) | アルコール性疲労改善剤 | |
JP2011132174A (ja) | 持久力向上剤 | |
CN108697679B (zh) | 含氨基酸的组合物 | |
JP2009112227A (ja) | カプサイシン含有飲料 | |
JP2008050269A (ja) | 経口摂取物 | |
KR101177888B1 (ko) | 숙취 예방 및 해소용 조성물 | |
JP4948056B2 (ja) | 疲労の予防又は改善剤 | |
JP2006199641A (ja) | 鉄吸着性高分子物質及び鉄含有高分子物質ならびにこれらの製造方法 | |
JP4131770B2 (ja) | 健康食品 | |
JP5384697B2 (ja) | 抗炎症剤及び抗酸化剤 | |
JP4319969B2 (ja) | 液体調味料 | |
JPH0881372A (ja) | 赤血球数の減少に起因する医学的症状の予防及び改善剤 | |
KR102591256B1 (ko) | 닭가슴살을 포함하는 고단백 음료 조성물 및 이의 제조방법 | |
JP2005239686A (ja) | 脂肪燃焼促進組成物及び該組成物を含有する食品又は医薬品 | |
JP7083254B2 (ja) | β-ヒドロキシ-β-メチル酪酸カルシウム塩(HMBCa)の苦味が低減された飲食品組成物 | |
US20050003047A1 (en) | Intestinal mineral absorption capacity improver | |
JP2017043592A (ja) | ニンニク等及び低塩分濃度の味噌を含有する組成物 | |
JP5997425B2 (ja) | オルニチン含有組成物 | |
WO2019022219A1 (ja) | ノルアドレナリンの分泌促進用アミノ酸組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2552889 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10585879 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005703552 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005703552 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10585879 Country of ref document: US |